Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for CellSeed's Days Payable or its related term are showing as below:
TSE:7776'
s Days Payable Range Over the Past 10 Years
Min: 9.18 Med: 35.55 Max: 692.6
Current: 59.76
During the past 13 years, CellSeed's highest Days Payable was 692.60. The lowest was 9.18. And the median was 35.55.
TSE:7776's Days Payable is ranked worse than 63.62% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs TSE:7776: 59.76
CellSeed's Days Payable
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
stayed the same
CellSeed Days Payable Related Terms
CellSeed Days Payable Historical Data
* Premium members only.
The historical data trend for CellSeed's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7776 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, CellSeed's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellSeed Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CellSeed's Days Payable distribution charts can be found below:
* The bar in red indicates where CellSeed's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
CellSeed's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CellSeed (TSE:7776) has a Days Payable of 0.00 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CellSeed and its competitors. Over the past decade, CellSeed's Days Payable has ranged from 9.18 to 692.60. According to the industry distribution chart, CellSeed ranks #446 out of 701 companies in the Biotechnology industry, placing it in the top 63.6%.
Is CellSeed's Days Payable too high?
CellSeed's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 9.18 to a high of 692.60. Based on the distribution chart, CellSeed ranks #446 out of 701 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CellSeed has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CellSeed's Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CellSeed ranks #446 out of 701 companies for Days Payable. This places CellSeed in the lower half of its industry. The industry median Days Payable is 112.84. Historically, CellSeed's own Days Payable has ranged from 9.18 to 692.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on CellSeed and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellSeed's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellSeed stock overvalued right now?
Based on GuruFocus' analysis, CellSeed (TSE:7776) is currently considered Significantly Overvalued. The stock's GF Value™ is 円162.45, compared to a current price of 円226.00 — trading 39.1% above its estimated fair value. The current Days Payable is 0.00. CellSeed's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For CellSeed (TSE:7776), the current Days Payable is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellSeed (TSE:7776) Overvalued in 2026?
Based on GuruFocus' analysis, CellSeed stock appears to be overvalued.
The current stock price of 円226.00 is trading 39.1% above its estimated GF Value™ of 円162.45.
GuruFocus considers CellSeed to be Significantly Overvalued.
Key valuation signals for TSE:7776:
Days Payable: 0.00
GF Value™: 円162.45 vs. price of 円226.00 (39.1% above fair value)
No single metric tells the full story. See the TSE:7776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellSeed Inc is a Japanese biotechnology company. The company is involved in the research, development, marketing, and sale of cell-sheet regenerative medicines, such as epithelial cell sheets for corneal and esophageal regeneration; regenerated cardiac patches to treat heart diseases; cell sheets for periodontal tissue regeneration; and regenerated cartilage sheets for the treatment of osteoarthritis.
55GF Score
Get the complete analysis for TSE:7776
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7776 has been successfully added to your 
